Image

Pediatric Prospective Personalized Immune and Target Identification Trial

Pediatric Prospective Personalized Immune and Target Identification Trial

Non Recruiting
1-19 years
All
Phase N/A

Powered by AI

Overview

PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.

Description

PPROSPERITIT will identify specific molecular changes by using genomic sequencing technologies in refractory/recurrent or very high-risk pediatric CNS tumors. The study will employ an analytically validated comparison of a selection of targeted agents/immune therapies on the basis of commercially available comprehensive genomic profiling FoundationOneHeme panel (F1Heme, comprising DNA and RNA analysis) vs selection of agents based on more complex DNA/RNA/Protein based analyses. This will be coupled to a computer algorithm that uses preexisting definitions and prioritization of target-agent pairs to assign patients by actionable mutation results to a targeted treatment. The selection of targeted agents will be performed by a multidisciplinary molecular tumor board, but the recommended treatment will not be a part of the PPROSPERTIT study.

Eligibility

Inclusion Criteria:

  1. Patient Informed consent form must be appropriately obtained under the applicable local and regulatory requirements. Each patient must sign a consent form prior the enrollment to document their willingness to participate.
  2. The subject is male or female, aged 1 - 19 years
  3. The subject must have a histologically proven recurrent/ refractory or very high-risk CNS tumors
  4. Patients must be in good overall physical condition, which allows tumor biopsy
  5. Patients must have a life expectancy of at least 3 months.
  6. Patients must have a tumor amenable to image-guided or direct vision biopsy and be willing and able to undergo a tumor biopsy and/or blood taking for molecular profiling.
  7. Patients must be accessible for follow-up.

Exclusion Criteria:

  1. Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  2. Pregnant and/or breastfeeding women, if applicable
  3. No intention to treat the patient.

Study details
    Central Nervous System Neoplasms
    Pediatric Cancer
    GEN1 Gene Mutation
    Tumor
    Brain

NCT04859543

Masaryk University

20 August 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.